A Multi-Centre, Tolerability Study of a Cannabidiol-enriched Cannabis Herbal Extract for Chronic Headaches in Adolescents: the CAN-CHA Protocol

- 4 Manik Chhabra¹, Evan C. Lewis², Robert Balshaw³, Breanne Stewart^{4,5}, Zina Zaslawski⁶, Trinity
- 5 Lowthian⁷, Zahra Alidina⁷, Melila Chesick-Gordis⁷, Wenli Xie⁵, Britt I. Drögemöller⁸, Galen
- 6 E.B. Wright¹, Kathryn A Birnie⁹, Katelynn E Boerner¹⁰, Vivian W. L. Tsang^{5, 10}, Samantha Lee
- 7 Irwin¹¹, Daniela Pohl ¹², Alexander G Weil¹³, Erick Sell¹², Erika Penz¹⁴, Amy Robson-
- 8 MacKay¹⁵, Sophia Mbabaali³, Stephanie Blackman^{16,17}, Shanlea Gordon¹⁰, Jane Alcorn^{18,19},
- 9 Richard J. Huntsman^{18,20}, Tim F Oberlander¹⁰, G Allen Finley^{16,17}, Lauren E Kelly^{1,6}
 - 1. Department of Pharmacology & Therapeutics, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada
 - 2. Neurology Centre of Toronto, Toronto ON, Canada
 - 3. George and Fay Yee Centre for Healthcare Innovation, University of Manitoba, Winnipeg, Manitoba, Canada
 - 4. Quality Management in Clinical Research (QMCR), University of Alberta, Edmonton, AB, Canada
 - 5. Maternal Infant Child and Youth Research Network (MICYRN), Vancouver, British Columbia, Canada
 - 6. Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, MB, Canada
 - 7. Youth research partners

1

2

3

10 11 12

13

14

15 16

17

18

19 20

21

22

23

24

2526

27

28 29

30

31

32 33

34

35

36

37

38

39

40

41 42

43

44

45

- 8. Department of Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
- 9. Department of Anesthesiology, Perioperative and Pain Medicine, University of Calgary, AB, Canada
- 10. Department of Pediatrics, BC Children's Hospital Research Institute, University of British Columbia, Vancouver, BC, Canada
- 11. University of California, San Francisco (UCSF) Child and Adolescent Headache Program. Department of Neurology, UCSF Weill Institute for Neurosciences, UCSF Benioff Children's Hospitals.
- 12. Division of Neurology, Children's Hospital of Eastern Ontario, University of Ottawa ON, Canada.
- 13. Pediatric Neurosurgery, Department of Surgery, Sainte Justine Hospital, University of Montreal, Montreal, Quebec, Canada
- 14. Department of Medicine, College of Medicine, University of Saskatchewan, Saskatchewan, Canada
- 15. Department of Psychiatry, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada
- 16. Department of Anesthesia, Pain Management and Perioperative Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
- 17. Center for Pediatric Pain Research, IWK Health, Halifax, Nova Scotia, Canada
- 18. Cannabinoid Research Initiative of Saskatchewan, University of Saskatchewan, Saskatoon, SK, Canada

19. College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada 20. Department of Pediatrics, Royal University Hospital, University of Saskatchewan, Saskatoon, SK, Canada Word count 5743 **Short title** Cannabis for Chronic Headaches in Adolescents **Corresponding Author** Lauren E Kelly PhD, MSc, BMedSci, CCRP Assistant Professor, Dept. of Pharmacology and Therapeutics, University of Manitoba Scientific Director, Canadian Childhood Cannabinoid Clinical Trials (www.C4Trials.org) 417 – 753 McDermot Ave, Winnipeg Manitoba R3E0T6 Email: lauren.elyse.kelly@gmail.com Phone: 204 272 3190

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

Discussion

Abstract

Introduction Cannabis products have been used in the management of headaches in adults and may play a role in pediatric chronic pain. Canadian pediatricians report increasing use of cannabis for the management of chronic headaches, despite no well-controlled studies to inform its dosing, safety, and effectiveness. The aim of our clinical trial is to determine the dosing and safety of a Cannabidiol (CBD)-enriched Cannabis Herbal Extract (CHE) for the treatment of chronic headaches in adolescents. Methods and analysis Youth, parents and an expert steering committee co-designed this tolerability study. Twenty adolescents (aged 14 to 17 years), with a chronic migraine diagnosis for more than 6 months that has not responded to other therapies, will be enrolled into an open label, dose escalation study across three Canadian sites. Study participants will receive escalating doses of a CBD-enriched CHE (MPL-001 with a THC:CBD of 1:25), starting at 0.2-0.4 mg/kg of CBD per day escalating monthly up to 0.8-1.0 mg/kg of CBD per day. The primary objective of this study is to determine the safety and tolerability of CBD-enriched CHE in adolescents with chronic migraine. Secondary objectives of this study will inform the development of subsequent randomized controlled trials and include investigating the relationship between the dose escalation and change in the frequency of headache, impact and intensity of pain, changes in sleep, mood, function, and quality of life. Exploratory outcomes include investigating steady-state trough plasma levels of bioactive cannabinoids and investigating how pharmacogenetic profiles affect cannabinoid metabolism among adolescents receiving CBD-enriched CHE.

This protocol was co-designed with youth and describes a tolerability clinical trial of CBDenriched CHE in adolescents with chronic headaches that have not responded to conventional therapies. This study is the first clinical trial on cannabis products in adolescents with chronic headaches and will inform the development of future comparative effectiveness clinical trials. Trial registration: CAN-CHA trial is registered with ClinicalTrials.gov with a number of register NCT05337033. **Keywords:** Cannabidiol; migraine, chronic headache; safety; adolescents; medical cannabis

Introduction

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

Globally, chronic headaches are one of the major causes of disability among adolescents. The World Health Organization classifies it under the top ten disabling health conditions, [1, 2] with a prevalence of 7.8% in adolescents 14 years of age or older [3-5]. In the US alone, the total annual cost incurred by pediatric headache is estimated around \$1.1 billion [6]. Adolescents with chronic headaches often experience reduced quality of life, sleep disruption, anxiety, fatigue, limb pain, dizziness, overuse of medications and academic challenges [7]. Despite advancements in the therapeutic management of chronic pain, treatment of chronic headache disorders in adolescents remains challenging. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), triptans, gabapentin, neuromodulation devices and ergotamine are used for the acute treatment of migraine [8, 9]. Preventive migraine therapies are limited in availability, efficacy, and authorization for use in the adolescent population. Topiramate is the only FDA approved preventive treatment for migraine in adolescents [1, 10, 11]. In other areas of medicine, cannabinoids have shown therapeutic potential in adolescents where conventional medications fail, including treatment resistant epilepsy, and chemotherapy-induced nausea and vomiting [12]. In adults, use of cannabis products is increasing for the treatment of headaches and migraines [13]. An observational study reported that 36% of adult cannabis users are using cannabis to relieve symptoms related to migraine and/or headaches. Further, this study reported that the use of cannabis products in adults led to an average reduction of 3.6 points on a 10-point intensity of headache scale [14, 15]. Despite promising observational data in adults, a paucity of literature exists that demonstrates the tolerability of cannabis for the treatment of chronic headaches in adolescents. Cannabidiol (CBD) and Tetrahydrocannabinol (THC) are the principal active

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

cannabinoids which have a number of potential therapeutic applications [16]. CBD, which is not associated with the same intoxicating effects of THC, acts as a negative allosteric modulator of CB1 receptors in the endocannabinoid system [17]. CBD potentiates anandamide-mediated intrinsic neurotransmission [18], and has antioxidant and anti-inflammatory activity [19]. Canadian studies have demonstrated the safety and tolerability of CBD-enriched CHE in children with refractory epilepsy [20, 21]. Huntsman et al reported on the preliminary results of the CARE-E trial where a 1:20 THC:CBD CHE oil was found to be well tolerated in children, and THC plasma concentrations were below levels associated with intoxication despite CBD doses of up to 12 mg/kg per day [21]. In Canada, recreational markets have increased cannabis accessibility and there is increasing interest in managing chronic headaches off-label with cannabinoids, self-guided in the absence of evidence [22]. The paucity of clinical trial data in children is due to many historical challenges with studying cannabis products and cannabinoids, resulting from legal difficulties in obtaining products, variable product quality control and the stigma associated with illegal drug use, and particularly with children. The current reality warrants the need to conduct robust interventional studies establishing the tolerability, safety, and efficacy of cannabis in adolescents with chronic headaches. Here we describe a protocol for CAN-CHA (CANnabis for Chronic Headaches in Adolescents) trial, an open-label dose escalation study to establish the tolerability of a CBDenriched Cannabis Herbal Extract (CHE) in adolescents with chronic headaches. CAN-CHA is funded by the SickKids Foundation, sponsored by the University of Manitoba and has received approvals from Health Canada and research ethics board. CAN-CHA is registered with ClinicalTrials.gov (NCT05337033).

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

Methods and analysis **Primary Objective** To determine the safety and tolerability of escalating doses of a CBD-enriched CHE in adolescents with chronic headaches. **Secondary Objectives** 1. To investigate the relationship between the dose-escalation with headache-free days. 2. To monitor the effect of CBD-enriched CHE oil on the intensity of pain related to chronic headaches. 3. To evaluate the effect of CBD-enriched CHE oil on sleep, mood, and function in adolescents with chronic headaches. 4. To explore the impact of chronic headaches on quality of life. **Exploratory Objectives** 1. To investigate the relationship between the dose-escalation and steady-state trough levels of bioactive cannabinoids/endocannabinoids. 2. To study pharmacogenetic variations among adolescents receiving CBD-enriched CHE oil. **Study Population** We will recruit 20 adolescents across three study sites: Halifax, Toronto, and Vancouver. To be eligible to participate in this study, an individual must meet all of the following criteria: 1. Adolescents between 14-17 years of age at the time of screening

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

investigator)

2. Diagnosed with Chronic Migraine according to ICHD-3: headache (migraine-like or tension-type like) occurring on 15 or more days per month for more than 3 months, which on at least 8 days per month have features of migraine headache [23]. 3. Failed at least two preventive treatment options on the grounds of tolerability and/or efficacy, including but not limited to antidepressants (tricyclic antidepressant or selective norepinephrine reuptake inhibitor), magnesium, gabapentin, topiramate, beta-blockers, memantine, and/or non-pharmacological therapies including nutraceuticals and botox. 4. Females who have reached menarche must have a negative serum pregnancy test during screening 5. Must be willing to engage with psychology and physiotherapy throughout the trial as appropriate. Adolescents meeting any of the following criteria will be excluded from the study: 1. As per the investigator judgment, the participant is not an ideal candidate due to a personal issue or medical condition that is likely to impede in the successful completion of the study 2. Participants with a history of post-concussion headache or new daily persistent headache 3. Participants with a diagnosis of medication overuse headache 4. Participants with cardiac, renal, or hepatic disease (assessed by the site investigator) 5. Participants with complex regional pain syndrome-II 6. Participants with abnormal ECG findings at baseline (as determined by the

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

7. Participants who are on the following medications: opioids, antipsychotics, antimanic. barbiturates, benzodiazepines, muscle relaxants, sedatives, or tramadol 8. Participants with developmental delay or impairments including autism, cerebral palsy, or intellectual disability 9. Participants with a personal or family history of schizophrenia or psychotic disorders 10. Participants who are/plan to become pregnant within the study period or within three months of interventional product discontinuation 11. Participants who cannot commit to using contraception, refraining from recreational cannabis use and driving throughout the study period Withdrawal criteria Study participants may withdraw from the study at any point. If a participant's headaches worsen or they suffer from intolerable treatment related adverse effects, they will be withdrawn from the study. Participants who become pregnant during the study period, do not attend follow-up visits, or do not comply with the prescribed interventional drug regimen will be withdrawn from the study. Participants will be given the option to only withdraw from the study intervention, these participants will continue to be followed up for safety assessments till the end of study. All participants withdrawn from the study will be included in the final report at the end of the study for transparency. Intervention The investigational product for our study is a CBD-enriched CHE, MPL-001, purchased from MediPharm Labs. MPL-001 is a CBD-enriched CHE where each ml of oil contains 2 mg of THC and 50 mg of CBD dissolved in coconut/palm-based medium chain triglycerides (MCT) carrier oil. The MPL-001 (CBD:THC 25:1) oil used in this study contains lemon-peppermint flavoring

agents. Manufacturing of MPL-001 occurs following Good Manufacturing Practices includes the following steps: harvesting of plant, followed by weighting, and drying. Further, dried plants are subjected to bucking, ethanolic extraction, filtration of cannabinoid ethanolic solution, and evaporation of ethanol, this leaves over acidic cannabis resin. Subsequently, cannabis resin is decarboxylated (activated) and mixed with oil. The oil is made available in a glass bottle sealed with child lock caps, stored and labeled at the study central pharmacy according in accordance with the Cannabis Act, 2018 and the Health Canada Division 5 Food and Drugs Act [24]. All the study participants will receive an escalating dose starting at 0.2-0.4 mg/kg of CBD per day with dose increases (0.2 mg/kg/day increments) happening monthly to a maximum of 0.8-1.0 mg/kg of CBD per day. This dosing strategy reflects the current clinical practice of study investigators and well below the maximum dose of CBD-enriched CHE of 10-12 mg/kg/day previously well tolerated in children with epilepsy [21]. Participants will be provided with dosing calendars (Fig. 2) and be instructed to take their daily dose bid with 25% of the dose in the morning and 75% of the daily dose in the late afternoon to mimic the diurnal variation [25] in the endocannabinoids and prevents adolescents from having to take cannabis during school hours. Fig 2. CAN-CHA dosing calendar.

Study design

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

CAN-CHA is a multicenter, open-label dose-escalation study to determine the tolerability of MPL-001 in adolescents with treatment refractory chronic migraine. A traditional 3+3 dose finding design was not practical as all participants would not receive the lowest cannabinoid dose and the recommended "start low and go slow" approach to titration. The trial will be conducted in three Canadian centers. CAN-CHA will consist of three different phases: baseline (1 month) without intervention, treatment (4 months of escalating doses) and weaning (1 month). All

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

participants and their caregivers will be invited to complete a pre- and post-study survey about their experiences in the trial to inform future research. Patient and public involvement CAN-CHA trial was designed in collaboration with youth from the KidsCAN Young Persons' Research Advisory Group (YRPAG) and from the Solutions for Kids in Pain (SKIP) network. The Canadian Collaborative for Childhood Canadianoid Therapeutics (C4T) Parent Advisory Committee provided insight on the outcome measurement tools and the consent form. Three youth advisors (TL, ZA, MC-G) with chronic migraines have been involved throughout the study design process and will continue to advise on recruitment strategies, designing materials, reporting and dissemination. **Baseline Phase** Eligible adolescents will be asked by their healthcare providers if they are interested in learning more about this research study. A study team member, who is not involved in the patients' care, will present the study, review the consent documents and answer any questions from the patients and their families. Adolescents who meet the inclusion criteria, assent, and whose caregiver's consent to participate will then begin a baseline period. Baseline will consist of one month period without intervention to estimate headache frequency and severity, as well as mood, sleep, and pain before administering the intervention to the participants. Participants will be asked to maintain a daily electronic headache diary that will include reporting on the severity of headaches, associated pain, sleep, absences from work/school and adverse events. Participants will complete age-validated scales on sleep related impairment, anxiety, depression, positive mood, pain interference, family impact and goal attainment scaling [26-31] as described in the Fig 1. A blood sample will be drawn from the study participants to measure liver transaminases

(ALT/AST) and creatinine, measure endocannabinoids and detect pregnancies, while saliva will be sampled for extraction of genomic DNA to allow for genotyping of pharmacogenetic variants.

ECGs (within 3 months of screening or done at the time of screening) will be recorded at baseline to ensure there are no cardiac electrical activity concerns.

Fig 1. CAN-CHA schedule of events as per SPIRIT guidelines

Treatment Phase

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

Following the one-month baseline period, study participants will receive CBD-enriched CHE oil, MPL-001 with a dosing calendar and administration pamphlet shipped directly to their homes from the trial coordinating centre. A handout on cannabis oil administration co-created with the youth advisors and will be provided to all study participants and their families that will also have a video component. There will also be a demonstration by the research coordinator at the first study visit using olive oil in a product bottle. The study participants will be instructed to administer the investigational product at a starting dose of 0.2-0.4 mg/kg/day divided into two doses (BID, 25% in the morning and 75% in the evening after school) each day for one month. Dose-escalation schedule during the treatment phase is described in Table 1. Participants will continue to complete a daily electronic headache diary to monitor symptoms and adverse effects. During all follow up visits, participants and their caregivers will be asked to complete validated outcome measurement tools alongside the PedsOL TM Family Impact Module assessment, and Self-directed goal attainment. Blood samples will be collected prior to starting the next dose level, at study visits and will be used to evaluate changes and variability in cannabinoid pharmacokinetics with escalating doses, confirm pregnancies, and monitor liver enzymes and creatinine over time.

Table 1. Dosing schedule for CAN-CHA evaluating a CBD-enriched CHE from visit 2 to visit 6

Visit	CBD total daily dose	Frequency	Duration
Visit 2	0.2-0.4 mg/kg/day	BID	1 month
Visit 3	0.4-0.6 mg/kg/day	BID	1 month
Visit 4	0.6-0.8 mg/kg/day	BID	1 month
Visit 5	0.8-1 mg/kg/day	BID	1 month

Weaning Phase: After the baseline phase (one month, no treatment) and the treatment phase (four months, escalating doses), participants will start the weaning schedule. Weaning includes incrementally reducing the dose (by 0.2 mg/kg CBD every week) leading to complete discontinuation of the study product. The complete weaning schedule is detailed in Table 2. The intervention will be discontinued by visit 7. If the parents, adolescents, and healthcare providers feel that there was improvement while on the intervention, participants will discuss the continued authorization of medical cannabis with the enrolling physician, caregivers and their healthcare team.

Table 2. The weaning schedule which begins at visit 6 and ends at visit 7

Visit 6	CBD total daily dose	Frequency	Duration
Week 1	0.6-0.8 mg/kg/day	BID	7 days
Week 2	0.4-0.6 mg/kg/day	BID	7 days
Week 3	0.2-0.4 mg/kg/day	BID	7 days
Week 4	0 mg/kg/day	BID	7 days

Dosing rationale and calculations

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

Data on the pharmacokinetics related to cannabinoids in adolescents are extremely lacking. In the current study, the CBD dose is extrapolated from safety data obtained in clinical trials in children and adults with refractory epilepsy [32-38]. CBD was found to be safe and welltolerated in children with refractory epilepsy at a dose of up to 20 mg/kg/day [32, 33, 35, 38, 39]. We aim to keep the CBD dose as low as possible to limit adverse events and reduce costs for families should we confirm a tolerable dose is effective in future randomized controlled trials. The use of THC is associated with some risk of developing adverse effects of the central nervous system, [40, 41] however, THC possesses its central pain-relieving potential at very low doses. much lower than would be expected from recreational cannabis exposures [42]. Previous studies on a 1:20 THC:CBD CHE oil in children reported that plasma THC levels following doses of up to 12 mg/kg/day suggested a low risk for THC intoxication [21]. The quantity of THC in our study product is 1 mg per mL with maximum THC doses only reaching 0.05 mg/kg/day, which we do not expect to be associated with any adverse psychoactive reactions. In this study, the maximum dose of CBD will be less than 10 percent of the recommended dose of CBD in the previous studies conducted in the pediatric population [43]. In order to maintain the accuracy and consistency in the dosing regimen of study participants across all the study centers, the mid-point of the dose range will be selected to calculate the desired dose based upon the weight of the participants. Participants will be weighed at each study visit to assist in tracking changes in appetite; however, the dose calculation will be based on the weight taken at baseline. The final dose will be calculated by rounding off (0.5 mL of MPL-001). This will help in achieving improved precision and will ease administration of the investigational product to the study participants. For example, an adolescent weighing 50 kg will receive a starting total daily dose containing 15 mg of CBD (0.3 mg/kg/day) and take 4 mLs in the morning and 11 mLs in the afternoon.

Dose limiting toxicities (DLTs)

Adverse events will be categorized using the Common Terminology Criteria for Adverse Events (CTCAE version 5.0 dated 27 Nov 2017). If any of the following DLTs occur the participant will not move up to the next dose level. Dose escalations will not be reattempted but the participant shall remain in CAN-CHA should no other DLTs occur. DLTs include:

- Parental/youth report complaints of moderate mood elevation defined as exaggerated feelings of well-being which is disproportionate to the events and stimuli (Euphoria Grade 2)
- 2. Somnolence Grade 2 which includes moderate sedation (sleepiness and drowsiness) that limits instrumental activities of daily living
- 3. Cannabis-attributed diarrhea, Grade 2 or more defined as an increase of 4 6 stools per day over baseline; moderate increase in ostomy output compared to baseline; limiting instrumental activities of daily living

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

4. Unexplained tachycardia (w/out pain, fever, anemia etc.) requiring medical intervention 5. Unexplained hypotension requiring medical intervention 6. Non-infectious conjunctivitis Grade 2 defined as moderate decrease in visual acuity (best corrected visual acuity 20/40 and better or 3 lines or less decreased vision from known baseline) characterized by inflammation, swelling and redness to the conjunctiva of the eye. 7. Serious adverse events requiring hospitalization 8. Discretion of the participant, physician, or parents **Primary Outcome** The frequency and type of cannabis-related adverse events among study participants will be assessed daily throughout the study. Adverse events will be reported daily and reviewed at study visits. **Secondary Outcomes** 1. The frequency of headache measured using headache-free days [assessed: daily throughout the study]. Reported number of headache-free days per month during the study period 2. The average intensity of pain due to chronic headaches as measured using an 11-point Numeric Rating Scale (NRS) [assessed: daily throughout the study] [44]. Reported for each study as a percentage change in average daily pain intensity due to chronic headaches on the numeric rating scale (NRS) from baseline to each follow up visit

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

3. The impact of pain on participants' quality of life using the PROMIS Pediatric Pain Interference—Short Form 8a [assessed: at visits 1,2,3,4,5,6 and 7] [26]. Reported as a percentage change in the scores from baseline value 4. The quality of sleep will be recorded using the PROMIS Pediatric Sleep-Related Impairment– Short Form 8a scale [45], [assessed: at visits 1,2,3,4,5,6 and 7] Reported as a percentage change in scores from baseline value 5. Changes in anxiety will be measured using the PROMIS Pediatric Short Form v2.0 -Anxiety - 8a scale [46] [assessed: at visits 1,2,3,4,5,6 and 7]. Reported as percentage change in scores from the baseline value 6. Change in mood will be evaluated using two tools PROMIS Pediatric Short Form v2.0 -Depressive Symptoms 8a scale and the PROMIS Pediatric Positive Affect – Short Form 8a. [29, 47] [assessed: at visits 1,2,3,4,5,6 and 7]. Reported as a percentage change in scores from baseline value 7. Change in self-directed goal attainment (participant and parent reported) [assessed: monthly throughout the study [30]. Reported as a percentage toward a physical, mental and social by participant at each monthly visit 8. Change in scores of PedsQL TM Family Impact Module, Version 2.0 [assessed: monthly throughout the study [31]. Reported as percentage change in scores from the baseline value 9. Steady-state trough plasma levels of bioactive cannabinoids THC, CBD, 11-OH-THC, 7-OH-CBD, and endocannabinoids [assessed: monthly throughout the study]. Reported as a plasma concentration relative to each dose increase/decrease and according to genotype

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

10. Genetic polymorphisms within genes encoding for cytochrome P450 enzymes and the pglycoprotein transporter and their association with plasma levels of THC, CBD, and their active metabolites in the study participants **Assessments** Participants will be enrolled in the study for six months. De-identified participant data will be collected electronically in a Research Electronic Data Capture (REDCap) database or paper copies will be provided based on participants' preferences. Assessments completed on paper will be kept as source documents at each study site and entered into REDCap by study staff. The following includes a detailed description of all planned assessments. **Physical examination** During the baseline and close out visits (visit 7), participants will undergo physical assessments, but weight will be reported at every visit to potentially signal changes in appetite. Blood work will assess liver function and renal safety, plasma concentration of cannabinoids, and pregnancy status. At the time of screening, participants will receive an electrocardiogram as per standard practice at each site should they not have had one in the previous 3 months. Electronic headache diary The daily diary was developed in collaboration with the youth advisors as described above. Administration will incorporate best practices in the use of daily diaries in adolescents, and feedback from patients with chronic pain and families interviewed about the use of in-home longitudinal ecological momentary assessment tools [48]. The purpose of the diary is to monitor and report headache characteristics, including intensity (Numeric Rating Scale; NRS), headachefree days, use of the rescue medication, and potential headache triggers (e.g., low sleep). Electronic diaries will be completed by the participants using REDCap. Adverse events will be

assessed daily with flags to research coordinators to review changes. The NRS is a validated tool that will be used to record daily self-reports of headache intensity from visit 1 until the end of the study [49]. Participants will rate the intensity of pain from 0 to 10, 0 means no hurt, 10 means the worst hurt you could ever imagine. The efficacy of the investigational product in treating the chronic headaches will be assessed in reducing the intensity of headache from baseline to each follow-up visit. Daily data from the electronic headache diaries will be transferred to the server. Based on pain intensity reported on the NRS, the study participant will be categorized into the severity of the headaches. Mild headache will vary in intensity between 1-5, moderate between 6-8, and severe between 9-10 [50]. A complete list of the daily headache diary questions are provided in Table 3. All the study participants will be given an option of using an electronic wrist worn device (actigraphy), provided at no cost to them by the study team, to help keep track of the number of hours slept per night.

Table 3: Electronic daily headache diary questions

1.	How many hours did you sleep last night?
2.	Did you have anything to eat before taking your first dose of the study
	medication?
3.	Did you take both doses of study medication today? If no, tell us why not?
	(open text)
4.	Did you have any headaches today?
5.	Rate your baseline/average pain level today, on a scale from 0-10

6.	Rate your highest pain level today, on a scale from 0-10
7.	Rate your lowest pain level today, on a scale from 0-10
8	Did you take any other medications today for any reason? If yes, please list the medication and frequency. For example, Tylenol – 3 regular strength tabs.
9.	Did you avoid attending any events (school/extracurricular/social) today due to headaches?
10.	Did your parent(s) or caregiver miss/avoid attending events (work/extracurricular/social) today due to your headache?
11.	Did you see physiotherapist or psychologist today?
13.	Did you experience any of the following symptoms today? (checklist) nausea, vomiting, diarrhea, drowsiness, fatigue, sleepiness, seizures or convulsions, decreased appetite, increased appetite, dizziness, dry mouth, irritability, something else (open text)
14.	Is there anything else you would like to share with us about your day? (open text)

PROMIS measures

Patient-Reported Outcomes Measurement Information System (PROMIS) evaluates social, mental, and physical health of adults and children [51]. We will be using the PROMIS tools to

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

measure pain interference, sleep, depressive symptoms, emotions, and family's quality of life. These tools will be completed by the study participants. The following PROMIS measure will be administered by the study participants. Pediatric Pain Interference - Short Form 8a scale The Pediatric Pain Interference PROMIS tool assesses the self-reported consequences of pain on the essential aspects of a participant's life. It measures the extent to which pain interferes with cognitive, emotional, social, physical, and recreational activities. The pediatric pain interference scale is non-disease specific, and the items utilize a 7-day recall period (items include the phrase "the past 7 days"). Varni et al. describe the strong psychometric properties of the PROMIS Pediatric Pain Interference Scale [26]. **Pediatric Sleep-Related Impairment - Short Form 8a scale** The Pediatric Sleep-related Impairment is a PROMIS tool, which assesses perceptions of sleepiness during awake hours and sleep-related impairments during the day. Mainly this tool assesses sleepiness during the daytime, sleep offset, and its impact on cognition, other daily activities, as well as emotional impact. The Pediatric Sleep-Related Impairment - Short Form 8a scale has demonstrated good validity and internal consistency [27]. Pediatric Depressive Symptoms - Short Form 8a scale v2.0 Pediatric Short Form v2.0 - Depressive Symptoms 8a is a PROMIS tool which is used for assessment of negative mood states, including sadness or guilt, self-criticism, self-perceived worthlessness, loneliness, interpersonal alienation (social cognition) and decreased positive affect and engagement. However, this scale does not assess somatic symptoms associated with depression, such as changes in appetite and sleeping patterns. Pediatric Short Form v2.0 -

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

Depressive Symptoms 8a scale has demonstrated good test-retest reliability, and validity of administration across groups [28]. Pediatric Positive Affect - Short Form 8a scale The Pediatric Positive Affect scale is PROMIS tool used for the assessment of positive or rewarding feelings and moods, including elation, pride, affection, pleasure, joy, engagement, excitement, happiness, and contentment. The short form of Pediatric Positive Affect scale is an efficient, accurate, and valid assessment of positive affect in adolescents and good reliability has been reported [47]. Pediatric Anxiety Symptoms- Short Form 8a scale v.2.0 The pediatric short form v2.0 Anxiety scale is a PROMIS tool used to assess the self-reported fear (fearfulness, panic), anxious misery (worry, dread), hyperarousal (tension, nervousness, restlessness), and somatic symptoms related to arousal (racing heart, dizziness). The literature reports excellent reliability and validity of the Pediatric Short Form v2.0 - Anxiety - 8a scale [29]. **Goal attainment Scaling** Goal attainment scaling is a patient-derived and reported outcome measure in which participants select their goals in areas where they would like to improve function [30]. Participants will be asked to select three goals at their screening appointment which could include physical, social, academic, or personal goals that they hope to improve on throughout the study period. In this, scaling goals are weighted with the importance (on a 0-10 scale) and difficulty (also on a 0-10 scale). **PedsQLTM Family Impact Module**

Pediatric quality of life family impact module aims to measure the effect of the child's chronic health condition on the family and parents. The PedsQL examines the domains of physical, emotional, social, cognitive, worry and communication to provide an overview of quality of life and impact on families. The PedsQL scale has demonstrated well defined validity and reliability [31].

Cannabinoid and metabolite assessment

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

To establish the relationship between dose-escalation and steady-state trough plasma concentrations (Css, Min) of the bioactive cannabinoids, we will collect blood samples before each dose escalation. At the first visit the study nurse will ask participants what methods they would like to employ to reduce needle pain. They will be offered evidence-based strategies including distraction and breathing techniques, use of a topical anesthetic and preferred positioning for blood draws [52]. Cannabinoid levels will be assessed using a previously described Liquid Chromatography-Mass Spectrometry (LC-MS/MS) method validated as per US FDA guidelines [53]. The blood sample from the study participants will be drawn into the heparinized lithium Barricor vacutainers ® (BD Canada, Mississauga, ON). The collected blood will be centrifuged for 10 minutes at 1500 rpm to separate the plasma from the blood. The separated plasma will be stored at – 80 °C until analysis. An LC-MS/MS method will be used to quantify the plasma concentration of THC, CBD, 11-OH-THC, 7-OH-CBD, and Cannabichromene. Stock solutions of cannabinoids and their respective stable isotope-labeled internal standards (Cerilliant Corp., Round Rock, TX) will be prepared in methanol at 1 mg/mL and stored at -20 °C until use. Stock solutions will be serial diluted using blank human plasma to develop calibration curves. Low, medium, and high-quality control (QC) samples will determine acceptance of the analytical run. QC and calibration samples will be prepared fresh each day

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

samples are analyzed. Calibration curves will be constructed from a plot of the peak area ratios of the cannabinoid and its respective internal standard against the nominal concentration. The linearity of the calibration curves will be determined with a linear least-squares regression analysis using 1/X as a weighting factor. Using FDA bioanalytical guidance, all calibration curves will be linear (r2 > 0.99) and intra- and inter-day precision and accuracy will be within 15%, except at the limit of quantification which will need to be within 20%. For all QC samples for a given run calculated concentrations will be within 15% of their nominal values. The plasma sample extraction will involve addition of internal standard working solution (10 µL) followed by protein precipitation with cold acetonitrile and removal of lipids using Agilent Captiva EMR-Lipid well plates. Supernatant will be transferred to borosilicate tubes and dried under filtered air for 30 minutes at 37°C. Samples will be reconstituted with 200 mL mobile phase and 100 μL transferred into HPLC inserts, 5 µL will be further injected onto an Agilent Phenyl-hexyl smallbore (2.1 × 12.5 mm, 5 µm) column and guard column maintaining the column temperature at 30°C to separate cannabinoids. Mobile phase A (water containing 0.1 mM ammonium formate) and B (methanol containing 0.1 mM ammonium formate) will separate the cannabinoids using a 10 minute gradient method with a flow rate of 250 L/min. Positive ion mode electrospray ionization (ESI), with an ion spray voltage of 5500 V, will be used to conduct multiple reaction monitoring (MRM) for quantification of CBD (quantifier ion m/z 315.1>193.2; qualifier ion m/z 315.1>259.2), THC (quantifier ion m/z 315.1>193.1; qualifier ion m/z 315.1>259.2), 11-OH-THC (quantifier ion m/z 331.1>193.1; qualifier ion m/z 331.1>201.0), CBC (quantifier ion m/z 315.1>193.2; qualifier ion m/z 315.1>259.2), CBD-d3 (318.2>196.1), THC-d3 (318.2>196.1), 11-OH-THC-d3 (334.2>196.1), and CBC-d9 (324.3>202.2) using a ABSciex 6500 QTRAP mass spectrometer (ABSciex, Concord, ON, Canada) and MultiQuant 3.0.1 Software. The

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

temperature, gas source 1, gas source 2, curtain gas, entrance potential, and collision activated dissociation gas were set to 600°C, 70, 60, 50, 10 V, and 10, respectively. The experienced team at the Cannabis Research Initiative of Saskatchewan, University of Saskatchewan will conduct all the analyses of the samples collected from all the three study sites. The samples will be analyzed in the three batches starting within the three months of the collections. The stability analysis of cannabinoids stored at -80°C for three months indicates excellent stability as described previously [20]. Pharmacogenomic analyses Genomic DNA will be extracted from saliva samples using a QIAmp DNA extraction kit at the University of Manitoba and genotyping will be performed using the Illumina Global Screening Array (GSA) v3 array on the iScan array scanner. The GSAv3 GWAS arrays have been designed to capture both common and rare genetic variation, including all variants that have been shown by the Clinical Pharmacogenetics Implementation Consortium to affect the function of the selected candidate genes [54]. Genotyped variants and samples will undergo standard quality control procedures in PLINK 1.9 [55]. Imputation of non-genotyped variants will be performed using the Michigan Imputation Server, including the Haplotype Reference Consortium data as a reference and genetically-determined ancestry will be assessed with EIGENSOFT v5 [56]. Association between these variants and response outcomes will be performed using logistic regression. Health care utilization Costs are an important consideration for families caring for an adolescent with a chronic illness, and are especially concerning for families accessing cannabis oils [57]. Participants in this study will provide consent to access their administrative health records for a pre and post study of

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

healthcare utilization to be designed, reviewed and approved in the future. During CAN-CHA, measures of absences from school and work for participants and caregivers, hospitalizations and the use of rescue medicines will be captured to inform building blocks for future health technology assessment. To reduce participant burden, access to health records will also ensure that the use of all rescue medications is documented should there be an admission to the emergency department or inpatient unit. Sample size CAN-CHA is a tolerability study, designed to evaluate the safety of escalating doses of a cannabidiol-enriched CHE. Given the within-participant study design, a sample size of 20 study participants (common for early phase trials) should provide a reasonable characterization of the pattern of adverse event frequency and severity as dosing increases. To provide more generalizable data we will recruit these participants across three pediatric chronic pain/headache programs in Halifax, Vancouver, and Toronto, Canada. Data collection, management and sharing Data collection will be the responsibility of the study team at each site under the supervision of the site investigators (TFO, ECL, GAF) and trial sponsor (LEK, University of Manitoba). Investigators and research coordinators will be responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data reported. All source documents will be completed in a neat, legible manner to ensure accurate interpretation of data. Hardcopies of the study visit measurement tool will be provided as source documents for each participant enrolled in the study. Data recorded in the electronic case report form (eCRF) derived from source documents should be consistent with source documents. Clinical and laboratory data will be entered into REDCap (Research Electronic Data Capture), [58] a 21 CFR Part 11-compliant data

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

capture system provided by the Women and Children's Health Research Institute at the University of Alberta, Edmonton. REDCap includes password protection and internal data quality checks, such as automatic range checking, to identify data that appear inconsistent, incomplete, or inaccurate to the study team for verification. Clinical data will be entered directly from the source documents. Full de-identified datasets will be available from the corresponding author upon reasonable request and review by the trial steering committee. Statistical analysis The primary statistical analyses will be a descriptive summary of the pattern of incidence and severity of adverse events across dosage levels. Adverse event severity grading is assigned using CTCAE definitions as described above. Conventional summary statistics will be used to describe baseline characteristics and other outcomes (means, standard deviations, as well as medians, range, and interquartile range (IQR) for numerical variables; counts and percentages for categorical variables). Adverse events will be reported overall (duration of the study period) and by dosage level (study month). Medians, ranges and IOR will be provided for the concentrations of CBD, THC, and the major metabolites at each sampling point. The ratio of concentration of parent compound to metabolites and endocannabinoids will also be summarized to explore variability in cannabinoid metabolism. Severity, frequency, and relationship of treatment emergent AEs to study intervention will be presented by system organ class and MEDRa coded. All serious adverse events will be reported to pharmacovigilance programs including Health Canada and the Canadian Paediatric Surveillance Program along with regulatory bodies including research ethics boards, the data safety monitoring board and trial steering committee. The secondary outcomes including pain, sleep impairment, depression, positive affect, anxiety, and goal attainment scores will be summarized at each timepoint; within-participant change from

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

baseline of these measures will also be summarized (both absolute and percentage change) but this trial is underpowered, and not designed to evaluate efficacy. **Ethics and dissemination** CAN-CHA received a No Objection Letter from Health Canada (Dec 2022), registered with Clinical Trials.gov (NCT05337033). The study was approved by the University of Manitoba Health Research Ethics Board (HS25503- B2022:037. An institutional cannabis research license is received in Sep 2022, and we expect to enroll our first participant in Spring 2023. Written informed consent will be taken from all the participants and from the legal guardians for the participants who will be below 16 years of age. We plan to disseminate our findings of the CAN-CHA trial by presenting them to conferences and publishing them in an open-access journal. **Discussion** In Canada, adolescents with refractory headache disorders are using cannabis products off-label to manage their symptoms, self-guided in the absence of evidence [59]. Chronic headaches are often resistant to standard drug therapies in adolescents, resulting in school absenteeism, withdrawal from social activities and can cause significant stress for families [60]. Based on anecdotal reports, parents of children with chronic headaches found cannabinoids to be effective for the management of headache[1], but there remains minimal data available to inform dosing or safety. CAN-CHA is a tolerability study designed with youth and parents that will investigate the safety of escalating doses up to 1mg/kg/day of CBD-enriched CHE in adolescents. This represents the first study evaluating a cannabis product, providing valuable knowledge on the safety and dosing of a CBD-enriched CHE in children with chronic pain. The CAN-CHA trial is an open label with a small sample size, underpowered to evaluate efficacy. This study will inform dose selection for a larger scale randomized clinical trial comparing a CBD-enriched

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

CHE oil to placebo (on top of standard of care) for adolescents with chronic headache. Given the high prevalence of chronic headaches, severe morbidity, and current lack of effective treatment options, the successful outcomes from this research project will have the potential to create meaningful impact for the lives of Canadian adolescents. **Supporting information S1.** SPIRIT checklist: Recommended items to address in a clinical trial protocol and related documents. **S2.** Approval by ethics committee. **S3**. Study protocol reviewed by ethics committee. **Abbreviations** AE: Adverse Events; BMI: Body Mass Index; CBD: Cannabidiol; CHE: Cannabis Herbal Extract; CNS: Central Nervous System; eCRF: electronic case report form; GMP: Good Manufacturing Practices; NRS: Numeric Rating Scale; NSAIDs: Non-steroidal Antiinflammatory Drugs; REDCap: Research Electronic Data Capture; THC: delta 9 – Tetrahydrocannabinol **Ethics and dissemination** The study was approved by the University of Manitoba Health Research Ethics Board (HS25503- B2022:037). We plan to disseminate our findings of the CAN-CHA trial open-access publication. **Author's contributions** LEK is the principal Investigator; led the proposal and protocol development. ECL, GAF, and TFO are the qualified investigators contributed to study design and to development of the proposal. TL, ZA, MCG, are the youth research partners, RB is biostatistician, BS is trial

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

coordinator, and MC is PhD trainee; drafted and revised manuscript. All authors provided insights in study design, read, and approved the final manuscript. Availability of data and material Access to the protocol and a deidentified dataset may be provided upon reasonable request to **LEK** and approval by the Clinical Trial Steering Committee. **Funding** This work was supported by the Hospital for Sick Children Foundation and the Canadian Institutes of Health Research grant number N120-1028. An investigational product for this trial has been purchased from MediPharm Labs. This organization has played no role in the design, conduct or reporting of the trial. **Competing interest LEK** is the Scientific Director for The Canadian Collaborative for Childhood Canabinoid Therapeutics (C4T) academic research team. She holds funding from the Canadian Institutes of Health Research, Canadian Cancer Society, Research Manitoba, the Sick Kids Foundation, the Children's Hospital Research Institute of Manitoba, the University of Manitoba and a Mitacs Accelerate award in partnership with Canopy Growth. Dr. Kelly is also a member of the Scientific Advisory Board for Health Products Containing Cannabis at Health Canada and a member of the Board of Directors of the Canadian Consortium for the Investigation of Cannabinoids (CCIC). **RJH** is a clinical lead for both the Cannabinoid Research Initiative of Saskatchewan and C4T. He is developing a research protocol in which cannabis products will be supplied in kind by JMCC Corporation. He is a co-chair of the Scientific Advisory Committee for Health Products Containing Cannabis at Health Canada. **KEB's** time is supported by a

fellowship from the Canadian Child Health Clinician Scientist Program, and she currently holds unrelated funding from the Society of Pediatric Psychology, BC Children's Hospital Research Institute, Canadian Institutes of Health Research, ZonMw: The Netherlands Organization for Health Research and Development, and the CHILD-BRIGHT Network. ECL has received speaking honoraria from Spectrum Therapeutics, Biome Grow, MedReleaf and Miravo Healthcare. He holds a non-salaried position as the Chief Medical Advisor for the JMCC Group. He is the Vice President of Neurology Services for Numinus, a psychedelic medicine treatment and research company. He is a member of the Expert Committee of the Medical Cannabis Clinicians Society (MCCS) in the United Kingdom and sits on the Advisory Councils for Cannabis Patient Advocacy & Support Services (CPASS) and MedCan. SLI In the last 12 months, Dr. Irwin has received honoraria for authoring a chapter for the Canadian Pharmacy Association (CPhA) and for doing an online lecture for NeuroDiem. She also receives compensation for scientific consulting (Impel NeuroPharma Inc, Biohaven Pharmaceuticals and Lundbeck A/S) and has had research support from the Duke Clinical Research Institute. MC has been granted the 2022 Research Manitoba-George & Fay Yee Centre for Healthcare Innovation in Health Research PhD Studentship Award. RB, BS, TL, ZA, MCG, BID, GEB, KAB, VWLT, DP, AGW, ES, EP, ARM, SM, ZZ, SB, SG, JA, TFO, and GAF have no potential conflict of interest to declare. **Acknowledgements:** We are thankful to Dr Thierry Lacaze-Masmoniteil for providing insights during the design of the study and all of the C4T members who have been consulted on protocol development and mentorship.

References

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

1. Seshia SS, Wang SJ, Abu-Arafeh I, Hershey AD, Guidetti V, Winner P, et al. Chronic daily headache in children and adolescents: a multi-faceted syndrome. Can J Neurol Sci.

- 696 2010;37(6):769-78. Epub 2010/11/10. doi: 10.1017/s0317167100051428. PubMed PMID: 21059537.
- Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia.
- 700 2007;27(3):193-210. Epub 2007/03/27. doi: 10.1111/j.1468-2982.2007.01288.x. PubMed PMID: 17381554.
- Castillo J, Muñoz P, Guitera V, Pascual J. Kaplan Award 1998. Epidemiology of chronic
 daily headache in the general population. Headache. 1999;39(3):190-6. Epub 2004/12/23. doi:
 10.1046/j.1526-4610.1999.3903190.x. PubMed PMID: 15613213.
- 705 4. Lantéri-Minet M, Auray JP, El Hasnaoui A, Dartigues JF, Duru G, Henry P, et al.
- 706 Prevalence and description of chronic daily headache in the general population in France. Pain. 2003;102(1-2):143-9. Epub 2003/03/07. doi: 10.1016/s0304-3959(02)00348-2. PubMed PMID: 12620605.
- Grande RB, Aaseth K, Gulbrandsen P, Lundqvist C, Russell MB. Prevalence of primary
 chronic headache in a population-based sample of 30- to 44-year-old persons. The Akershus
 study of chronic headache. Neuroepidemiology. 2008;30(2):76-83. Epub 2008/02/16. doi:
 10.1159/000116244. PubMed PMID: 18277081.
- 713 6. Law EF, Palermo TM, Zhou C, Groenewald CB. Economic Impact of Headache and Psychiatric Comorbidities on Healthcare Expenditures Among Children in the United States: A
- Retrospective Cross-Sectional Study. Headache. 2019;59(9):1504-15. Epub 2019/09/15. doi:
- 716 10.1111/head.13639. PubMed PMID: 31520418; PubMed Central PMCID: PMCPMC6818708.
- 717 7. Bellini B, Arruda M, Cescut A, Saulle C, Persico A, Carotenuto M, et al. Headache and
- 718 comorbidity in children and adolescents. J Headache Pain. 2013;14(1):79. Epub 2013/09/26.
- 719 doi: 10.1186/1129-2377-14-79. PubMed PMID: 24063537; PubMed Central PMCID:
- 720 PMCPMC3849985.
- 721 8. Pardutz A, Schoenen J. NSAIDs in the Acute Treatment of Migraine: A Review of
- 722 Clinical and Experimental Data. Pharmaceuticals (Basel). 2010;3(6):1966-87. Epub 2010/06/17.
- 723 doi: 10.3390/ph3061966. PubMed PMID: 27713337; PubMed Central PMCID:
- 724 PMCPMC4033962.
- 9. Ravishankar K, Chakravarty A, Chowdhury D, Shukla R, Singh S. Guidelines on the diagnosis and the current management of headache and related disorders. Ann Indian Acad
- 727 Neurol. 2011;14(Suppl 1):S40-59. Epub 2011/08/19. doi: 10.4103/0972-2327.83100. PubMed 728 PMID: 21847329; PubMed Central PMCID: PMCPMC3152170.
- 729 10. Oermann CM, Retsch-bogart GZ, Quittner AL, Gibson RL, McCoy KS, Montgomery AB,
- et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatric Pulmonology. 2010;45(11):1121-34. doi:
- 732 http://dx.doi.org/10.1002/ppul.21301.
- 733 11. Kacperski J, Kabbouche MA, O'Brien HL, Weberding JL. The optimal management of
- headaches in children and adolescents. Ther Adv Neurol Disord. 2016;9(1):53-68. Epub
- 735 2016/01/21. doi: 10.1177/1756285615616586. PubMed PMID: 26788131; PubMed Central PMCID: PMCPMC4710107.
- 12. Lochte BC, Beletsky A, Samuel NK, Grant I. The Use of Cannabis for Headache
- 738 Disorders. Cannabis Cannabinoid Res. 2017;2(1):61-71. Epub 2017/09/02. doi:
- 739 10.1089/can.2016.0033. PubMed PMID: 28861505; PubMed Central PMCID:
- 740 PMCPMC5436334.
- 741 13. Salazar CA, Tomko RL, Akbar SA, Squeglia LM, McClure EA. Medical Cannabis Use
- among Adults in the Southeastern United States. Cannabis. 2019;2(1):53-65. Epub 2019/03/01.
- 743 PubMed PMID: 30815638; PubMed Central PMCID: PMCPMC6388700.
- 744 14. Rhyne DN, Anderson SL, Gedde M, Borgelt LM. Effects of Medical Marijuana on
- Migraine Headache Frequency in an Adult Population. Pharmacotherapy. 2016;36(5):505-10.
- 746 Epub 2016/01/11. doi: 10.1002/phar.1673. PubMed PMID: 26749285.

- 747 15. Cuttler C. Spradlin A. Cleveland MJ. Craft RM. Short- and Long-Term Effects of
- 748 Cannabis on Headache and Migraine. J Pain. 2020;21(5-6):722-30. Epub 2019/11/13. doi:
- 749 10.1016/j.jpain.2019.11.001. PubMed PMID: 31715263.
- 750 16. Gonçalves J, Rosado T, Soares S, Simão AY, Caramelo D, Luís Â, et al. Cannabis and
- 751 Its Secondary Metabolites: Their Use as Therapeutic Drugs, Toxicological Aspects, and
- 752 Analytical Determination. Medicines (Basel). 2019;6(1). Epub 2019/03/01. doi:
- 753 10.3390/medicines6010031. PubMed PMID: 30813390; PubMed Central PMCID:
- 754 PMCPMC6473697.
- 755 17. Morales P, Goya P, Jagerovic N, Hernandez-Folgado L. Allosteric Modulators of the
- 756 CB(1) Cannabinoid Receptor: A Structural Update Review. Cannabis Cannabinoid Res.
- 757 2016;1(1):22-30. Epub 2016/01/01. doi: 10.1089/can.2015.0005. PubMed PMID: 28861476;
- 758 PubMed Central PMCID: PMCPMC5576597.
- 759 18. Pertwee RG. Pharmacology of cannabinoid receptor ligands. Curr Med Chem.
- 760 1999;6(8):635-64. Epub 1999/09/02. PubMed PMID: 10469884.
- 761 19. Benito C, Tolón RM, Pazos MR, Núñez E, Castillo AI, Romero J. Cannabinoid CB2
- receptors in human brain inflammation. Br J Pharmacol. 2008;153(2):277-85. Epub 2007/10/16.
- 763 doi: 10.1038/sj.bjp.0707505. PubMed PMID: 17934510; PubMed Central PMCID:
- 764 PMCPMC2219537.
- 765 20. Reithmeier D, Tang-Wai R, Seifert B, Lyon AW, Alcorn J, Acton B, et al. The protocol for
- the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study: a phase 1
- 767 dosage escalation study. BMC Pediatr. 2018;18(1):221. Epub 2018/07/10. doi: 10.1186/s12887-
- 768 018-1191-y. PubMed PMID: 29981580; PubMed Central PMCID: PMCPMC6035794.
- 769 21. Huntsman RJ, Tang-Wai R, Alcorn J, Vuong S, Acton B, Corley S, et al. Dosage Related
- 770 Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic
- 771 Encephalopathy: Preliminary Results of the CARE-E Study. Front Neurol. 2019;10:716. Epub
- 772 2019/07/25. doi: 10.3389/fneur.2019.00716. PubMed PMID: 31333569; PubMed Central
- 773 PMCID: PMCPMC6616248.
- 774 22. Rieder MJ. Is the medical use of cannabis a therapeutic option for children? Paediatr
- 775 Child Health. 2016;21(1):31-4. Epub 2016/03/05. doi: 10.1093/pch/21.1.31. PubMed PMID:
- 776 26941559; PubMed Central PMCID: PMCPMC4758425.
- 777 23. Headache Classification Committee of the International Headache Society (IHS) The
- 778 International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211.
- 779 Epub 2018/01/26. doi: 10.1177/0333102417738202. PubMed PMID: 29368949.
- 780 24. Rotermann M. Looking back from 2020, how cannabis use and related behaviours
- 781 changed in Canada. Health Rep. 2021;32(4):3-14. Epub 2021/04/22. doi: 10.25318/82-003-
- 782 x202100400001-eng. PubMed PMID: 33881274.
- 783 25. Vaughn LK, Denning G, Stuhr KL, de Wit H, Hill MN, Hillard CJ. Endocannabinoid
- signalling: has it got rhythm? British journal of pharmacology. 2010;160(3):530-43.
- 785 26. Varni JW, Stucky BD, Thissen D, Dewitt EM, Irwin DE, Lai JS, et al. PROMIS Pediatric
- 786 Pain Interference Scale: an item response theory analysis of the pediatric pain item bank. J
- 787 Pain. 2010;11(11):1109-19. Epub 2010/07/16. doi: 10.1016/j.jpain.2010.02.005. PubMed PMID:
- 788 20627819; PubMed Central PMCID: PMCPMC3129595.
- 789 27. Yu L, Buysse DJ, Germain A, Moul DE, Stover A, Dodds NE, et al. Development of short
- 790 forms from the PROMIS™ sleep disturbance and Sleep-Related Impairment item banks. Behav
- 791 Sleep Med. 2011;10(1):6-24. Epub 2012/01/19. doi: 10.1080/15402002.2012.636266. PubMed
- 792 PMID: 22250775; PubMed Central PMCID: PMCPMC3261577.
- 793 28. Varni JW, Magnus B, Stucky BD, Liu Y, Quinn H, Thissen D, et al. Psychometric
- 794 properties of the PROMIS ® pediatric scales: precision, stability, and comparison of different
- scoring and administration options. Qual Life Res. 2014;23(4):1233-43. Epub 2013/10/03. doi:
- 796 10.1007/s11136-013-0544-0. PubMed PMID: 24085345; PubMed Central PMCID:
- 797 PMCPMC4312615.

- 798 29. Irwin DE, Stucky B, Langer MM, Thissen D, Dewitt EM, Lai JS, et al. An item response
- analysis of the pediatric PROMIS anxiety and depressive symptoms scales. Qual Life Res.
- 800 2010;19(4):595-607. Epub 2010/03/10. doi: 10.1007/s11136-010-9619-3. PubMed PMID:
- 801 20213516; PubMed Central PMCID: PMCPMC3158603.
- 802 30. Gordon JE, Powell C, Rockwood K. Goal attainment scaling as a measure of clinically
- important change in nursing-home patients. Age Ageing. 1999;28(3):275-81. Epub 1999/09/04. doi: 10.1093/ageing/28.3.275. PubMed PMID: 10475864.
- 31. Varni JW, Sherman SA, Burwinkle TM, Dickinson PE, Dixon P. The PedsQL Family
- 806 Impact Module: preliminary reliability and validity. Health Qual Life Outcomes. 2004;2:55-. doi:
- 807 10.1186/1477-7525-2-55. PubMed PMID: 15450120.
- 808 32. Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, et al.
- 809 Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology.
- 810 2018;90(14):e1204-e11. Epub 2018/03/16. doi: 10.1212/wnl.000000000005254. PubMed
- 811 PMID: 29540584; PubMed Central PMCID: PMCPMC5890607.
- 812 33. Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, et al. Effect of
- Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. N Engl J Med.
- 814 2018;378(20):1888-97. Epub 2018/05/17. doi: 10.1056/NEJMoa1714631. PubMed PMID:
- 815 29768152.
- 816 34. Thiele E, Marsh E, Mazurkiewicz-Beldzinska M, Halford JJ, Gunning B, Devinsky O, et
- al. Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label
- 818 extension study. Epilepsia. 2019;60(3):419-28. Epub 2019/02/12. doi: 10.1111/epi.14670.
- 819 PubMed PMID: 30740695; PubMed Central PMCID: PMCPMC6850399.
- 820 35. Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in
- patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol.
- 822 2016;15(3):270-8. Epub 2016/01/03. doi: 10.1016/s1474-4422(15)00379-8. PubMed PMID:
- 823 26724101.
- 824 36. Raucci U, Pietrafusa N, Paolino MC, Di Nardo G, Villa MP, Pavone P, et al. Cannabidiol
- Treatment for Refractory Epilepsies in Pediatrics. Front Pharmacol. 2020;11:586110. Epub
- 826 2020/10/30. doi: 10.3389/fphar.2020.586110. PubMed PMID: 33117180; PubMed Central
- 827 PMCID: PMCPMC7550750.
- 828 37. Abu-Sawwa R, Scutt B, Park Y. Emerging Use of Epidiolex (Cannabidiol) in Epilepsy. J
- 829 Pediatr Pharmacol Ther. 2020;25(6):485-99. Epub 2020/08/26. doi: 10.5863/1551-6776-
- 830 25.6.485. PubMed PMID: 32839652; PubMed Central PMCID: PMCPMC7439947.
- 38. Devinsky O, Nabbout R, Miller I, Laux L, Zolnowska M, Wright S, et al. Long-term
- 832 cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial. Epilepsia.
- 833 2019;60(2):294-302. Epub 2018/12/26. doi: 10.1111/epi.14628. PubMed PMID: 30582156;
- 834 PubMed Central PMCID: PMCPMC7379690.
- 835 39. Miller I, Scheffer IE, Gunning B, Sanchez-Carpintero R, Gil-Nagel A, Perry MS, et al.
- 836 Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure
- Frequency in Dravet Syndrome: A Randomized Clinical Trial. JAMA Neurol. 2020;77(5):613-21.
- 838 Epub 2020/03/03. doi: 10.1001/jamaneurol.2020.0073. PubMed PMID: 32119035; PubMed
- 839 Central PMCID: PMCPMC7052786 compensation from Greenwich Biosciences during the
- 840 conduct of the study and grants, personal fees, and other compensation from Greenwich
- 841 Biosciences, nonfinancial support and other compensation from Dravet Syndrome Foundation,
- grants and nonfinancial support from Insys Pharmaceuticals, personal fees and nonfinancial
- support from BioMarin Pharmaceutical, Inc, and Upshire-Smith Laboratories, LLC, and grants,
- personal fees, and nonfinancial support from Zogenix, Inc, outside the submitted work. Dr
- Scheffer reported receiving other compensation from GW Pharmaceuticals during the conduct
- of the study; other from Zynerba Pharmaceuticals, Inc. Zogenix, Inc. Ovid Therapeutics, Inc.
- Marinus, and Ultragenyx Pharmaceutical, Inc, personal fees and other compensation from UCB,
- personal fees from GlaxoSmithKline, Eisai Co, Ltd, BioMarin Pharmaceutical, Inc, Nutricia, and

- 849 Xenon Pharmaceuticals, outside the submitted work; a patent to WO06/133508 issued; and
- research funding from the National Health and Medical Research Council, Health Research
- 851 Council of New Zealand, and National Institutes of Health. Dr Gunning reported serving on
- scientific advisory boards of GW Pharmaceuticals, Zogenix, Inc., and Ovid Therapeutics,
- 853 Inc/Takeda Pharmaceutical Company Limited; serving on the speaker's bureau for LivaNova
- plc; and serving as the principal investigator for trials sponsored by GW Research, Ltd, and
- 855 Zogenix, Inc. Dr Sanchez-Carpintero reported receiving research support from GW
- 856 Pharmaceuticals and Zogenix for clinical trials; serving on advisory boards for Novartis
- International AG, GW Pharmaceuticals, and Zogenix, Inc; and serving as a trial investigator for
- 858 GW Research, Ltd and Ovid Therapeutics, Inc/Takeda Pharmaceutical Company Limited. Dr
- 859 Gil-Nagel reported serving as an investigator, speaker, and advisory board member for Bial.
- 860 Eisai Co, Ltd, Esteve, UCB, GW Pharmaceuticals, GW Research, Ltd, Zogenix, Inc, Stoke
- Therapeutics, Sanofi, and Arvelle Therapeutics. Dr Perry reported participating on advisory
- boards for Upsher-Smith Laboratories, LLC, and Zogenix, Inc, as a consultant for Encoded
- Therapeutics, Inc, and as a trial investigator for GW Research, Ltd, and Zogenix, Inc. Dr Saneto
- reported serving as a principal investigator on the GW Research, Ltd, trials for Dravet Syndrome
- Foundation and TSC; on the data safety monitoring board for a clinical study sponsored by
- Reata Pharmaceuticals for Friedreich ataxia; as principal investigator on a study sponsored by
- Stealth Pharmaceutical for primary mitochondrial myopathy; as principal investigator on a study
- sponsored by Zogenix, Inc, in patients with Dravet syndrome; and on the speaker's bureau for GW Pharmaceuticals. No other disclosures were reported.
- 870 40. Rubino T, Realini N, Braida D, Guidi S, Capurro V, Viganò D, et al. Changes in
- hippocampal morphology and neuroplasticity induced by adolescent THC treatment are
- associated with cognitive impairment in adulthood. Hippocampus. 2009;19(8):763-72.
- 873 41. Murray CH, Huang Z, Lee R, de Wit H. Adolescents are more sensitive than adults to
- acute behavioral and cognitive effects of THC. Neuropsychopharmacology. 2022;47(7):1331-8.
- 42. Almog S, Aharon-Peretz J, Vulfsons S, Ogintz M, Abalia H, Lupo T, et al. The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients
- with chronic pain: A randomized, double-blinded, placebo-controlled trial. Eur J Pain.
- 878 2020;24(8):1505-16. Epub 2020/05/24. doi: 10.1002/ejp.1605. PubMed PMID: 32445190;
- PubMed Central PMCID: PMCPMC7496774 disclosures; Dr. Hayon, Mrs. Ogintz, Mrs. Abalia,
- and Mr. Lupo are employees of Syqe Medical; Dr. Vulfsons and Prof. Eisenberg received research support from Syge Medical.
- 882 43. Silva GD, Del Guerra FB, de Oliveira Lelis M, Pinto LF. Cannabidiol in the Treatment of
- 883 Epilepsy: A Focused Review of Evidence and Gaps. Front Neurol. 2020;11:531939. Epub
- 884 2020/11/17. doi: 10.3389/fneur.2020.531939. PubMed PMID: 33192966; PubMed Central
- 885 PMCID: PMCPMC7604476.
- 886 44. Birnie KA, Hundert AS, Lalloo C, Nguyen C, Stinson JN. Recommendations for selection
- 887 of self-report pain intensity measures in children and adolescents: a systematic review and
- quality assessment of measurement properties. Pain. 2019;160(1):5-18. Epub 2018/09/05. doi:
- 889 10.1097/j.pain.000000000001377. PubMed PMID: 30180088.
- 890 45. Hanish AE, Lin-Dyken DC, Han JC. PROMIS Sleep Disturbance and Sleep-Related
- 891 Impairment in Adolescents: Examining Psychometrics Using Self-Report and Actigraphy. Nurs
- 892 Res. 2017;66(3):246-51. Epub 2017/04/28. doi: 10.1097/nnr.000000000000217. PubMed
- 893 PMID: 28448375; PubMed Central PMCID: PMCPMC5426113.
- 894 46. Donnelly A, Fitzgerald A, Shevlin M, Dooley B. Investigating the psychometric properties
- of the revised child anxiety and depression scale (RCADS) in a non-clinical sample of Irish
- adolescents. J Ment Health. 2019;28(4):345-56. Epub 2018/02/16. doi:
- 897 10.1080/09638237.2018.1437604. PubMed PMID: 29447056.
- 898 47. Forrest CB, Ravens-Sieberer U, Devine J, Becker BD, Teneralli R, Moon J, et al.
- 899 Development and Evaluation of the PROMIS(®) Pediatric Positive Affect Item Bank, Child-

- 900 Report and Parent-Proxy Editions, J Happiness Stud. 2018;19(3):699-718. Epub 2018/05/16.
- 901 doi: 10.1007/s10902-016-9843-9. PubMed PMID: 29760578; PubMed Central PMCID:
- 902 PMCPMC5947961.
- 903 48. Heron KE, Everhart RS, McHale SM, Smyth JM. Using Mobile-Technology-Based
- 904 Ecological Momentary Assessment (EMA) Methods With Youth: A Systematic Review and
- 905 Recommendations. J Pediatr Psychol. 2017;42(10):1087-107. Epub 2017/05/06. doi:
- 906 10.1093/jpepsy/jsx078. PubMed PMID: 28475765.
- 907 49. Krebs EE, Carey TS, Weinberger M. Accuracy of the pain numeric rating scale as a
- 908 screening test in primary care. J Gen Intern Med. 2007;22(10):1453-8. Epub 2007/08/02. doi:
- 909 10.1007/s11606-007-0321-2. PubMed PMID: 17668269; PubMed Central PMCID:
- 910 PMCPMC2305860.
- 911 50. Birnie KA, McGrath PJ, Chambers CT. When does pain matter? Acknowledging the
- 912 subjectivity of clinical significance. Pain. 2012;153(12):2311-4. Epub 2012/09/22. doi:
- 913 10.1016/j.pain.2012.07.033. PubMed PMID: 22995250.
- 914 51. Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S, et al. The Patient-Reported
- 915 Outcomes Measurement Information System (PROMIS) developed and tested its first wave of
- adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol. 2010;63(11):1179-
- 917 94. Epub 2010/08/06. doi: 10.1016/j.jclinepi.2010.04.011. PubMed PMID: 20685078; PubMed
- 918 Central PMCID: PMCPMC2965562.
- 919 52. Trottier ED, Doré-Bergeron MJ, Chauvin-Kimoff L, Baerg K, Ali S. Managing pain and
- 920 distress in children undergoing brief diagnostic and therapeutic procedures. Paediatr Child
- 921 Health. 2019;24(8):509-35. Epub 2019/12/18. doi: 10.1093/pch/pxz026. PubMed PMID:
- 922 31844394; PubMed Central PMCID: PMCPMC6901171.
- 923 53. San Nicolas M, Villate A, Gallastegi M, Aizpurua-Olaizola O, Olivares M, Etxebarria N, et
- al. Analysis of cannabinoids in plants, marijuana products and biological tissues.
- 925 Comprehensive Analytical Chemistry. 90: Elsevier; 2020. p. 65-102.
- 926 54. Witte JS. Genome-wide association studies and beyond. Annu Rev Public Health.
- 927 2010;31:9-20 4 p following Epub 2010/03/20. doi: 10.1146/annurev.publhealth.012809.103723.
- 928 PubMed PMID: 20235850; PubMed Central PMCID: PMCPMC3997166.
- 929 55. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation
- 930 PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4:7. Epub
- 931 2015/02/28. doi: 10.1186/s13742-015-0047-8. PubMed PMID: 25722852; PubMed Central
- 932 PMCID: PMCPMC4342193.

- 933 56. Li Y, Willer C, Sanna S, Abecasis G. Genotype imputation. Annu Rev Genomics Hum
- 934 Genet. 2009;10:387-406. Epub 2009/09/01. doi: 10.1146/annurev.genom.9.081307.164242.
- 935 PubMed PMID: 19715440; PubMed Central PMCID: PMCPMC2925172.
- 936 57. Gibbard M, Mount D, Rassekh SR, Siden HH. Family attitudes about and experiences
- 937 with medical cannabis in children with cancer or epilepsy: an exploratory qualitative study.
- 938 CMAJ Open. 2021;9(2):E563-e9. Epub 2021/05/23. doi: 10.9778/cmajo.20200212. PubMed
- 939 PMID: 34021014; PubMed Central PMCID: PMCPMC8177908.
- 940 58. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic
- 941 data capture (REDCap)—a metadata-driven methodology and workflow process for providing
- translational research informatics support. Journal of biomedical informatics. 2009;42(2):377-81.
- 943 59. Grant CN, Belanger RE. Cannabis and Canada's children and youth. Paediatr Child
- 944 Health. 2017;22(2):98-102. Epub 2018/02/27. doi: 10.1093/pch/pxx017. PubMed PMID:
- 945 29480902; PubMed Central PMCID: PMCPMC5804770.
- 946 60. Öst E, Nisell M, Burgos CM, Frenckner B, Öjmyr-Joelsson M. Behavioral, emotional and
- 947 social functioning in children born with congenital diaphragmatic hernia. Pediatr Surg Int.
- 948 2018;34(6):653-61. Epub 2018/04/11. doi: 10.1007/s00383-018-4266-9. PubMed PMID:
- 949 29637256; PubMed Central PMCID: PMCPMC5954068.

Monthly study visit #	1	2	3	4	5	6	7
Follow up window (± 5 days)							
Informed consent	X						
Medical history and demographics	X						
MPL-001 intervention follow-up		Х	Х	X	X	W	
Concomitant medication review	X	X	X	X	X	X	X
Physical exam	X						X
dRxiv preprint doi: https://doi.org/10.1101/2023.08.04.23293647; this version posted August 7, 2023. The copyright holde which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint It is made available under a CC-BY 4.0 International license.	X If for this pre t in perpetuit	X	X	X	X	Х	X
Pregnancy test in females	X	X	X	X	X	X	X
Review of daily electronic headache diary	X	Х	X	X	X	X	X
Sleep related impairment scale	X	Х	X	X	X	X	X
Pain related interference scale	X	X	X	X	X	X	X
Family impact scale	X	X	X	X	X	X	X
Mood scales for anxiety, depression, and positive affects	X	X	X	X	X	X	X
Self-directed goal attainment	X	X	X	Х	X	X	X
Participant expectation survey	X						X
Blood samples (8mLs, approx.)	X	X	X	X	X	X	X
Saliva sample for pharmacogenomics							
Adverse event review		X	X	X	X	X	X
Drug accountability		X	X	X	X	X	X
Visit duration (minutes)	60	45	60	45	60	45	60

Where W = weaning begins

Use the light grey rectangles to fill out the corresponding number of days in the month. Please mark the boxes to indicate that you have administered the CBD-enriched cannabis herbal extract oil and took your medication with food. If you lose this form please email the research coordinator to send you an electronic copy.

	SUNDAY	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY	
Morning	mL	mL	mL	mL	mL.	mL	mL	
Afternoon	mL	mL	mL	mL	mL	mL	mL	
<u>ॐ</u> Morning	mL	mL	mL	mL	mL	mL	mL	
Afternoon	mL	mL	mL	mL	mL	mL	mL	
Morning	mL	mL	mL	mL	mL	mL	mL	
Afternoon	mL	mL	mL	mL	mL	mL	mL	
<u>ॐ</u> Morning	mL	mL	mL	mL	mL	mL	mL	
Afternoon	mL	mL	mL	mL	mL	mL	mL	
<u>ॐ:</u> Morning	mL	mL	mL	mL	mL	mL	mL	
Afternoon	mL	mL	mL	mL	mL	mL	mL	
			NO	TES				
						1mL =	_ drops of CBD oil	
Participant ID:	Vis	it #:	Date:		Physician Signature:			

BC - CO
Children's
Hospital









